International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(1):43-48.

Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients?
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi, Alireza Janbakhsh

Abstract


Background: In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections.

Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p<0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months.

Conclusions: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+.


Keywords


FISH; Hormone receptors; DFS; Trastuzumab

Full Text:

PDF

References


Payandeh M, Shahriari-Ahmadi A, Sadeghi M, et al. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status. Asian Pac J Cancer Prev. 2016; 17(3):1015-8.

Hosseini MS, Arab M, Nemati Honar B, et al. Age - specific incidence rate change at breast Cancer and its different histopathologic subtypes in Iran and Western countries. Pak J Med Sci.2013; 29(6):1354-7.

Cui H, Cheng Y, Piao SZ, et al. Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines. Cancer Cell Int. 2014; 14(1):10.

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127–37.

Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013; 33(3):411-7.

Rexer BN, Chanthaphaychith S, Dahlman K, et al. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res. 2014; 16(1):R9.

Banin Hirata BK, Maeda Oda JM, Losi Guembarovski R, et al. Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers. 2014; 2014:513158.

Keyhani E, Muhammadnejad A, Behjati F, et al. Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents. Asian Pac J Cancer Prev. 2013; 14(12):7651-6.

Bahreini F, Soltanian AR, Mehdipour P. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. 2015; 22(6):615-25.

Madani SH, Payandeh M, Sadeghi M, et al. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. Indian J Med Paediatr Oncol. 2016; 37(2):95-9.

Payandeh M, Khodarahmi R, Sadeghi M, et al. Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature. Iran J Cancer Prev. 2015; 8(2):125-8.

Erbil N, Dundar N, Inan C, et al. Breast cancer risk assessment using the gail model: a Turkish study. Asian Pac J Cancer Prev. 2015; 16(1):303-6.

Mohaghegh P, Yavari P, Akbari ME, et al. The Correlation between the Family Levels of Socioeconomic Status and Stage at Diagnosis of Breast Cancer. Iran J Cancer Prev. 2014; 7(4):232-8.

Qiao EQ, Ji M, Wu J, et al. Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer. Mol Clin Oncol. 2013; 1(4):703-10.

Ha JH, Seong MK, Kim EK, et al. Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients. J Breast Cancer. 2014; 17(1):33-9.

Varga Z, Noske A, Ramach C, et al. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer. 2013; 13:615.

Ghaffari SR, Sabokbar T, Dastan J, et al. Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). Asian Pac J Cancer Prev. 2011; 12(4):1031-4.

Shirsat HS, Epari S, Shet T, et al. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization. Indian J Pathol Microbiol. 2012; 55(2):175-9.

Sui W, Ou M, Chen J, et al. Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer. World J Surg Oncol. 2009; 7:83.

Park S, Park HS, Koo JS, et al. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer. 2012; 118(4):914-23.

DE Vargas Wolfgramm E, Gavioli CF, Entringer ML, et al. Histological profile and age at diagnosis of breast and ovarian tumors: A register-based study in Espirito Santo, Brazil. Mol Clin Oncol. 2013; 1(2):353-358.

Bertrand KA, Tamimi RM, Scott CG, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013; 15(6):R104.

Sofi GN, Sofi JN, Nadeem R, et al. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev. 2012; 13(10):5047-52.

Song Q, Huang R, Li J, et al. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China. PLoS One. 2013; 8(8):e72175.

Shomaf M, Masad J, Najjar S, et al. Distribution of breast cancer subtypes among Jordanian women and correlation with histopathological grade: molecular sub classification study. JRSM Short Rep. 2013; 4(10):2042533313490516.

Okita Y, Narita Y, Suzuki T, et al. Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Mol Clin Oncol. 2013; 1(6):995-1001.

Gultekin M, Eren G, Babacan T, et al. Metaplastic breast carcinoma: a heterogeneo disease. Asian Pac J Cancer Prev. 2014; 15(6):2851-6.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.